Please assess the completion status of the following clinical trial:

Trial Title: Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects;~2. Age \> 18 years;~3. Patients with steroid-dependent Crohn's disease, documented in the medical history, having suffered from at least one episode of relapse (CDAI \> 150) in the last 12 months. Patients should have been in clinical remission (CDAI \< 150) for at least four weeks, on stable therapy with at least 10 mg of methylprednisolone (or equivalent), or been on steroidal tapering after a recent relapse. Patients with intolerance or resistance to AZT/6-MP/MTX were eligible;~4. Patients willing and able to give written informed consent.~Exclusion Criteria:~1. Patients with Crohn's disease with intestinal sub-occlusion, or suspect of abdominal abscess, or with active perianal disease, or with clinically active disease at randomization (CDAI ≥150);~2. Patients already on therapy with immunosuppressant agents (AZT, 6-MP, MTX) for less than 4 months;~3. Patients having received therapy with infliximab (or other anti-TNF) in the previous 3 months;~4. Investigational treatments in the previous 3 months prior to randomization;~5. Pregnant women, or women who were not using valid birth-control measures, except those in surgical menopause; breast feeding;~6. Non collaborating subjects or those unable to be compliant with the treatment and the study schedules;~7. Severe concomitant diseases such as :~   1. patients with inadequate bone marrow reserve: WBC \< 3000 /mm3; PLTs \< 75000 /mm3; Hb \< 8 g/dl~  2. liver disease with total bilirubin ≥ 3 times the upper limit of normal (ULN), AST (GOT) ≥ 3x ULN, alkaline phosphatase ≥ 3x ULN~  3. renal disease with serum creatinine ≥ 3 mg/dl~  4. serious cardiac, allergic, lung, neurological diseases, neoplastic or pre-neoplastic disease~  5. diseases (other than Crohn's) requiring chronic steroid treatment;~8. Elective surgery already scheduled at the start of the study (NB: patients having undergone previous surgery for Crohn's disease could be enrolled, if the patient had fully recovered and had been in remission for at least 4 weeks);~9. Chronic use of alcohol; drug addiction;~10. Subjects with contra-indication to the use of steroids (i.e. systemic fungal infections);~11. Evidence of clostridium difficilis in the stools.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ery-dex (Type: EXPERIMENTAL): Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
- Placebo (Type: PLACEBO_COMPARATOR): placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues